A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests tirzepatide in people with obesity to see how it affects calorie burning and food intake. The study lasts several months and involves multiple visits to the study center. Tirzepatide is a new treatment effective in managing obesity and type 2 diabetes.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot have taken any weight loss drugs in the past 6 months.
How is the drug Tirzepatide different from other treatments for type 2 diabetes?
Who Is on the Research Team?
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive tirzepatide or placebo once weekly by subcutaneous injection
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Placebo
- Tirzepatide
Tirzepatide is already approved in United States, European Union, Canada, United Kingdom for the following indications:
- Type 2 diabetes
- Type 2 diabetes
- Type 2 diabetes
- Weight loss
- Moderate to severe obstructive sleep apnea
- Weight loss
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University